A New Era of Cancer Treatment

We have one of the leading pipelines in cell therapy within the industry

Our CAR pipeline currently includes our lead investigational therapy that has the potential to become a franchise and address a range of blood cancers, and next generation technologies. Our TCR pipeline includes investigational therapies that have the potential to address a range of solid tumors.

Chimeric Antigen Receptor (CAR)

Trial Area of Research Pre-Ind Phase 1 Phase 2/3

axicabtagene ciloleucel

ZUMA-1

DLBCL, PMBCL & TFL

ZUMA-5

Indolent NHL

ZUMA-6

DLBCL (PD-L1 mAb)

ZUMA-7

DLBCL (2nd line)

ZUMA-9 (Expanded Access)

Aggressive NHL

KTE-C19

ZUMA-2

MCL

ZUMA-3

Adult ALL

ZUMA-4

Pediatric ALL

ZUMA-8

CLL

Human anti-CD19 (2nd Gen)

NCI

Heme Malignancies

Humanized anti-CD19 Control CAR (3rd Gen)

Heme Malignancies

KITE-585 (anti-BCMA)

MM

KITE-796 (anti-CLL-1 Control CAR)

AML

T Cell Receptor (TCR)

Trial Area of Research Pre-Ind Phase 1 Phase 2/3

MAGE A3/A6

NCI

Solid Tumor

KITE-718 (MAGE A3/A6)

Solid Tumor

MAGE A3

NCI

Solid Tumor

HPV-16 E6 & E7

NCI

Cervical and HNC

KITE-439 (HPV-16 E7)

Cervical and HNC

KRAS

NCI

Solid Tumor

SSX-2

NCI

Solid Tumor

Neoantigens

NCI

Solid Tumor

DLBCL = diffuse large b-cell lymphoma

PMBCL = primary mediastinal b-cell lymphoma

TFL = transformed follicular lymphoma

NHL = non-Hodgkin lymphoma

CLL = chronic lymphocytic leukemia

MM = multiple myeloma

MCL = mantle cell lymphoma

AML = acute myeloid leukemia

ALL = acute lymphoblastic leukemia

Kite Pharma Expanded Access Policy

Treating physicians may request information about Expanded Access for a Kite Pharma therapy by contacting Kite Medical Information at 1-844-454-KITE.

Kite will evaluate these requests individually. Kite may provide physician requested Expanded Access for a Kite therapy for patients with no other available therapies and for patients who are not eligible to participate in a current Kite clinical trial. Kite will acknowledge receipt of the request via telephone call or email within 5 business days of receipt of the request.

Information on all Kite trials can be found on ClinicalTrials.gov.

Pursuant to the 21st Century Cures Act: the posting of policies by manufacturers and distributors shall not serve as a guarantee of access to any specific investigational therapy by any individual patient.